Renovos is transforming regenerative medicine through pioneering use of RENOVITE® nanoclay gels from world-class stem cell research. RENOVITE® formulations are injectable, bioactive, and can deliver and completely retain biologics within the target site of repair, allowing for 100x dose reduction, lower COGS and improved safety of potent biologics. Renovos’ mission is to unlock the full potential of regenerative medicine and help clinicians deliver safe and more efficacious treatments for tissue repair, addressing a $5.7bn orthobiologics market. Renovos has granted patents and a strong scientific and commercial team. The company is now raising funding to complete pre-clinical development and enable clinical trials in 2024.